Vir Biotechnology Inc
VIR5.100USD
+0.070+1.39%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
704.12MValor de mercado
PerdaP/L TTM
Mais detalhes de Vir Biotechnology Inc Empresa
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Informações da empresa
Código da empresaVIR
Nome da EmpresaVir Biotechnology Inc
Data de listagemOct 11, 2019
CEODr. Marianne De Backer, Ph.D.
Número de funcionários408
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 11
Endereço1800 Owens Street
CidadeSAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94158
Telefone14159064324
Sitehttps://www.vir.bio/
Código da empresaVIR
Data de listagemOct 11, 2019
CEODr. Marianne De Backer, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
Dr. Mark Eisner, M.D.
Dr. Mark Eisner, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Ms. Janet Napolitano, J.D.
Ms. Janet Napolitano, J.D.
Independent Director
Independent Director
--
--
Mr. Jason V. O'byrne
Mr. Jason V. O'byrne
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Vicki L. Sato, Ph.D.
Dr. Vicki L. Sato, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
Detalhamento da receita
FY2024
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
74.20M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 5 de jun
Atualizado em: qui, 5 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
SB Investment Advisers (UK) Limited
12.07%
BlackRock Institutional Trust Company, N.A.
10.40%
ARCH Venture Partners
9.34%
The Vanguard Group, Inc.
9.25%
GSK plc
6.19%
Other
52.75%
Investidores
Investidores
Proporção
SB Investment Advisers (UK) Limited
12.07%
BlackRock Institutional Trust Company, N.A.
10.40%
ARCH Venture Partners
9.34%
The Vanguard Group, Inc.
9.25%
GSK plc
6.19%
Other
52.75%
Tipos de investidores
Investidores
Proporção
Investment Advisor
28.96%
Investment Advisor/Hedge Fund
15.19%
Private Equity
13.70%
Venture Capital
10.23%
Hedge Fund
7.60%
Corporation
6.19%
Individual Investor
4.39%
Research Firm
1.90%
Foundation
1.13%
Other
10.73%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
530
124.95M
90.39%
-15.17M
2025Q1
571
125.80M
91.30%
-16.44M
2024Q4
568
122.14M
89.06%
-13.83M
2024Q3
554
118.76M
86.83%
-17.44M
2024Q2
572
119.53M
87.47%
-20.55M
2024Q1
564
122.68M
91.07%
-16.10M
2023Q4
577
121.87M
90.75%
-16.40M
2023Q3
578
123.93M
92.29%
-3.81M
2023Q2
574
125.10M
93.31%
+332.42K
2023Q1
568
121.09M
90.65%
+1.82M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
SB Investment Advisers (UK) Limited
16.68M
12.07%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.37M
10.4%
-298.87K
-2.04%
Mar 31, 2025
ARCH Venture Partners
12.92M
9.34%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
12.78M
9.25%
-323.13K
-2.47%
Mar 31, 2025
GSK plc
8.55M
6.19%
--
--
Apr 01, 2025
State Street Global Advisors (US)
5.73M
4.14%
+652.43K
+12.86%
Mar 31, 2025
Scangos (George A)
3.78M
2.73%
-550.77K
-12.72%
Apr 01, 2025
Dimensional Fund Advisors, L.P.
2.68M
1.94%
+768.95K
+40.14%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.30M
1.66%
+98.43K
+4.48%
Mar 31, 2025
OrbiMed Advisors, LLC
2.25M
1.63%
-970.37K
-30.15%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Global X Genomics & Biotechnology ETF
0.57%
ALPS Medical Breakthroughs ETF
0.47%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Invesco S&P SmallCap Health Care ETF
0.33%
Hypatia Women CEO ETF
0.18%
SPDR S&P Biotech ETF
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
WisdomTree US SmallCap Quality Growth Fund
0.09%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.87%
Global X Genomics & Biotechnology ETF
Proporção0.57%
ALPS Medical Breakthroughs ETF
Proporção0.47%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.46%
Invesco S&P SmallCap Health Care ETF
Proporção0.33%
Hypatia Women CEO ETF
Proporção0.18%
SPDR S&P Biotech ETF
Proporção0.17%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.1%
WisdomTree US SmallCap Quality Growth Fund
Proporção0.09%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
